<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298973</url>
  </required_header>
  <id_info>
    <org_study_id>Alcon2011-VIS-001</org_study_id>
    <nct_id>NCT01298973</nct_id>
  </id_info>
  <brief_title>Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions</brief_title>
  <official_title>Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the ability of Viscoat to ensure proper wound
      closure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ensure watertight, patient wound closure after clear corneal cataract incisions</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group will receive Saline to irrigate the wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viscoat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group will receive Viscoat to close the surgical wound</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viscoat</intervention_name>
    <description>One group will receive Viscoat for incision closure</description>
    <arm_group_label>Viscoat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>One group will receive Saline to irrigate the wound</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent, complete questionnaires, and likely to complete
             all visits

          -  Subject must be male or female, of any race, and at least 21 years old

          -  Undergoing uncomplicated cataract surgery with clear corneal incisions

        Exclusion Criteria:

          -  Subjects with known sensitivity or inappropriate responsiveness to any of the
             medications used in the post-operative course

          -  Acute or chronic disease or illness that would increase risk or confound study results
             (e.g., uncontrolled diabetes mellitus, immunocompromised,etc.)

          -  Uncontrolled systemic disease

          -  Corneal abnormalities (e.g., stromal, epithelial or endothelial dystrophies)

          -  Subjects who use concurrent topical or systemic medications that may impair healing,
             including but not limited to:antimetabolites,isotretinoin (Accutane) within 6 months
             of treatment, and amiodarone hydrochloride (Cordarone) within 12 months of treatment

          -  Subjects with a history of any of the following medical conditions, or any other
             condition that could affect wound healing: collagen vascular disease, autoimmune
             disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine
             disorders (including but not limited to unstable thyroid disorders and diabetes),
             lupus, and rheumatoid arthritis

          -  Concurrent participation or participation in the last 30 days in any other clinical
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Florida Eye Microsurgical Institute</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Physicians of Central Florida</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Annie Christensen</name_title>
    <organization>CRO</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

